<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"><channel><title>Dentistry News in Medical XPRT</title><link>https://alpha.medical-xprt.com/dentistry/news</link><description>Dentistry News in Medical XPRT</description><image><url>https://alpha.medical-xprt.com/images/logo.gif</url><link>https://alpha.medical-xprt.com/dentistry/news</link><title>Dentistry News in Medical XPRT</title></image><item><title>RevBio Receives Approval from the U.K.’s Regulatory Authority to Initiate a Clinical Trial for an Optimized Formulation of its Dental Bone Adhesive Biomaterial</title><link>https://alpha.medical-xprt.com/news/revbio-receives-approval-from-the-uk-s-regulatory-authority-to-initiate-a-clinical-trial-for-an-opti-1083870</link><description><![CDATA[RevBio, Inc., announced that it has received approval from the Medicines and Healthcare products Regulatory Agency in the United Kingdom to start a 15-patient clinical trial to examine the safety and efficacy of immediately stabilized dental implants following tooth extractions using an optimized formulation of Tetranite&reg;, the company&rsquo;s bone adhesive biomaterial.  Dr. Michael R. Norton, BDS, FDS, RCS(Ed), a London-based oral surgeon, noted lecturer, and former President of the Academy of Osseointegration, will serve as the chief investigator for this clinical trial. &ldquo;I am thrilled to be involved in this clinical trial which builds on the first one I completed earlier this year,&rdquo; said Dr. Norton. &ldquo;Since initiating the prior MHRA-approved study in the United Kingdom, RevBio has significantly improved the osteopromotive potential of its biomaterial.&rdquo;  RevBio has optimized its bone adhesive biomaterial primarily by adjusting the pH of the material as it undergoes its self-setting reaction. In addition, the company has also increased the porosity of the material. Benchtop and animal testing has shown that these changes have improved the material&rsquo;s biocompatibility with the gingival tissues that surround tooth extraction sites. These formulation changes have also increased the substitution rate of new bone formation without sacrificing the biomaterial&rsquo;s ability to adhere to bone. In fact, this formulation is more adhesive than the company&rsquo;s prior dental formulation.  Similar to Dr. Norton&rsquo;s prior study, this new clinical trial will focus specifically on anterior teeth located in the aesthetic or &ldquo;smile&rdquo; zone where the loss of a tooth is highly visible. Patients will receive temporary crowns at the time their implants are placed which will obviate a costly, complex, and lengthy bone grafting process for many patients, greatly accelerating the overall treatment timeframe.  &ldquo;We are excited to partner again with Dr. Norton who is a thought leader in advancing clinical practice in the field of implant dentistry,&rdquo; said Alan Pollack, RevBio&rsquo;s Senior Director of Dental Clinical Operations. &ldquo;The development of this new formulation has really advanced the company&rsquo;s ability to tune the biomaterial&rsquo;s performance to address anatomically-specific requirements.&rdquo;  ]]></description><pubDate>Thu, 15 Sep 2022 00:00:00 +0000</pubDate><guid>https://alpha.medical-xprt.com/news/revbio-receives-approval-from-the-uk-s-regulatory-authority-to-initiate-a-clinical-trial-for-an-opti-1083870</guid><category>bone graft</category><category>dental implant</category><category>osseointegration</category><category>clinical trial</category><category>healthcare product</category><category>surgery</category><category>oral surgery</category><category>bone formation</category><category>dental clinic</category><category>dental adhesive</category><category>clinical practice</category><category>clinical development</category><category>biomaterials</category><category>implant dentistry</category><category>bone implant</category><category>implant</category><category>biocompatibie</category><category>biomaterials implant</category><category>bone biomaterials</category><category>dental bone</category></item></channel></rss>
